Superworth

Atrium Therapeutics RNA

Drug Manufacturers - General, Healthcare
$8.55
+3.39%
Market cap
$146.3M
PE
n/m
one or more of the four quarters through 2026-06-30 missing
Forward PE
n/m
not a meaningful number
Price to sales
n/m
one or more of the four quarters through 2026-06-30 missing
EV/EBIT
n/m
not a meaningful number
Revenue, 12 months
n/m
one or more of the four quarters through 2026-06-30 missing
Net margin
n/m
one or more of the four quarters through 2026-06-30 missing
Free cash flow yield
n/m
not a meaningful number

Charts

Financials

Income statement for RNA, by quarter
Income statementQ1 FY25Q2 FY25Q1 FY26Q2 FY26
$1.6M$3.8M$19.6M$3M
R&D$6.9M$13.3M$16.7M$15.3M
SG&A$2.1M$3.4M$20.3M$10.3M
−$7.5M−$12.9M−$17.3M−$22.6M
Net income−$7.4M−$12.9M−$16.6M−$20.2M
−$0.44−$0.75−$0.97−$1.18
17.1M17.1M17.1M17.1M

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Atrium Therapeutics' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
RNAAtrium Therapeutics$146.3Mn/mn/an/mn/mn/m
NATRNatures Sunshine Products$211.5M11.9×20.2×0.4×+7%3.7%
LFVNLifevantage$73.5M14.7×19.4×0.4×−20%2.8%
SPROSpero Therapeutics$60.6M9.5×9.5×1.3×−3%15.7%
CRMDCorMedix$420.1M2.5×4.0×0.9×+281%40.5%
ATNMActinium Pharmaceuticals$45M4.0×3.3×n/mn/mn/m
ARVNArvinas$491.7M47.0×50.5×1.6×−15%2.9%
PBYIPuma Biotechnology$525.5M19.6×12.3×2.3×−3%11.6%
IRWDIronwood Pharmaceuticals$571.7M4.5×14.8×1.5×+26%33.4%
ZVRAZevra Therapeutics$599.8M10.9×12.2×4.4×+119%42.8%
COLLCollegium Pharmaceutical$770.9M19.1×19.1×1.0×+14%5.9%
Peer median$455.9M11.4×13.5×1.3×+7%11.6%

More on Atrium Therapeutics

Each number over time

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .